|
1
|
Parkin DM, Pisani P and Ferlay J: Global
cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar
|
|
2
|
Hoffman PC, Mauer AM and Vokes EE: Lung
cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allard WJ, Matera J, Miller MC, et al:
Tumor cells circulate in the peripheral blood of all major
carcinomas but not in healthy subjects or patients with
nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tewes M, Aktas B, Welt A, et al: Molecular
profiling and predictive value of circulating tumor cells in
patients with metastatic breast cancer: an option for monitoring
response to breast cancer related therapies. Breast Cancer Res
Treat. 115:581–590. 2009. View Article : Google Scholar
|
|
5
|
Schuster R, Bechrakis NE, Stroux A, et al:
Circulating tumor cells as prognostic factor for distant metastases
and survival in patients with primary uveal melanoma. Clin Cancer
Res. 13:1171–1178. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iinuma H, Okinaga K, Egami H, et al:
Usefulness and clinical significance of quantitative real-time
RT-PCR to detect isolated tumor cells in the peripheral blood and
tumor drainage blood of patients with colorectal cancer. Int J
Oncol. 28:297–306. 2006.PubMed/NCBI
|
|
7
|
Devriese LA, Bosma AJ, van de Heuvel MM,
Heemsbergen W, Voest EE and Schellens JH: Circulating tumor cell
detection in advanced non-small cell lung cancer patients by
multi-marker QPCR analysis. Lung Cancer. 75:242–247. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moreno JG, Miller MC, Gross S, Allard WJ,
Gomella LG and Terstappen LW: Circulating tumor cells predict
survival in patients with metastatic prostate cancer. Urology.
65:713–718. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cristofanilli M and Mendelsohn J:
Circulating tumor cells in breast cancer: Advanced tools for
‘tailored’ therapy? Proc Natl Acad Sci USA. 103:17073–17074.
2006.
|
|
10
|
Nagrath S, Sequist LV, Maheswaran S, et
al: Isolation of rare circulating tumour cells in cancer patients
by microchip technology. Nature. 450:1235–1239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoon SO, Kim YT, Jung KC, Jeon YK, Kim BH
and Kim CW: TTF-1 mRNA-positive circulating tumor cells in the
peripheral blood predict poor prognosis in surgically resected
non-small cell lung cancer patients. Lung Cancer. 71:209–216. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zieglschmid V, Hollmann C and Böcher O:
Detection of disseminated tumor cells in peripheral blood. Crit Rev
Clin Lab Sci. 42:155–196. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sieuwerts AM, Kraan J, Bolt-de Vries J, et
al: Molecular characterization of circulating tumor cells in large
quantities of contaminating leukocytes by a multiplex real-time
PCR. Breast Cancer Res Treat. 118:455–468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Blanc-Brude OP, Mesri M, Wall NR, Plescia
J, Dohi T and Altieri DC: Therapeutic targeting of the survivin
pathway in cancer: initiation of mitochondrial apoptosis and
suppression of tumor-associated angiogenesis. Clin Cancer Res.
9:2683–2692. 2003.PubMed/NCBI
|
|
16
|
Pennati M, Folini M and Zaffaroni N:
Targeting survivin in cancer therapy: fulfilled promises and open
questions. Carcinogenesis. 28:1133–1139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adida C, Berrebi D, Peuchmaur M,
Reyes-Mugica M and Altieri DC: Anti-apoptosis gene, survivin, and
prognosis of neuroblastoma. Lancet. 351:882–883. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bertazza L, Mocellin S, Marchet A, et al:
Survivin gene levels in the peripheral blood of patients with
gastric cancer independently predict survival. J Transl Med.
7:1112009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao W, Yang W, Li H, et al: Using
detection of survivin-expressing circulating tumor cells in
peripheral blood to predict tumor recurrence following curative
resection of gastric cancer. J Surg Oncol. 103:110–115. 2011.
View Article : Google Scholar
|
|
20
|
Shen C, Hu L, Xia L and Li Y: The
detection of circulating tumor cells of breast cancer patients by
using multimarker (Survivin, hTERT and hMAM) quantitative real-time
PCR. Clin Biochem. 42:194–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Daniel M, Peek GW and Tollefsbol TO:
Regulation of the human catalytic subunit of telomerase (hTERT).
Gene. 498:135–146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miura N, Horikawa I, Nishimoto A, et al:
Progressive telomere shortening and telomerase reactivation during
hepatocellular carcinogenesis. Cancer Genet Cytogenet. 93:56–62.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu CH, Lin SR, Hsieh JS, et al: Molecular
detection of disseminated tumor cells in the peripheral blood of
patients with gastric cancer: evaluation of their prognostic
significance. Dis Markers. 22:103–109. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang YL, Lee YC, Liao WY and Wu CT: The
utility and limitation of thyroid transcription factor-1 protein in
primary and metastatic pulmonary neoplasms. Lung Cancer.
44:149–157. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lazzaro D, Price M, de Felice M and Di
Lauro R: The transcription factor TTF-1 is expressed at the onset
of thyroid and lung morphogenesis and in restricted regions of the
foetal brain. Development. 113:1093–1104. 1991.PubMed/NCBI
|
|
26
|
Pelosi G, Fraggetta F, Pasini F, et al:
Immunoreactivity for thyroid transcription factor-1 in stage I
non-small cell carcinomas of the lung. Am J Surg Pathol.
25:363–372. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wicha MS: Cancer stem cells and
metastasis: lethal seeds. Clin Cancer Res. 12:5606–5607. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kalekou H and Miliaras D: Cytokeratin 7
and 20 expression in gallbladder carcinoma. Pol J Pathol. 62:25–30.
2011.PubMed/NCBI
|
|
29
|
Kawaguchi K and Shin SJ:
Immunohistochemical staining characteristics of low-grade
adenosquamous carcinoma of the breast. Am J Surg Pathol.
36:1009–1020. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Coban S, Ormeci N, Savaş B, et al:
Evaluation of Barrett’s esophagus with CK7, CK20, p53, Ki67, and
cyclooxygenase expressions using chromoendoscopical examination.
Dis Esophagus. May 16–2012.(Epub ahead of print).
|
|
31
|
Ross H, Martignoni G and Argani P: Renal
cell carcinoma with clear cell and papillary features. Arch Pathol
Lab Med. 136:391–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xi L, Nicastri DG, El-Hefnawy T, Hughes
SJ, Luketich JD and Godfrey TE: Optimal markers for real-time
quantitative reverse transcription PCR detection of circulating
tumor cells from melanoma, breast, colon, esophageal, head and
neck, and lung cancers. Clin Chem. 53:1206–1215. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG and Morrow M: AJCC Cancer Staging Handbook. 6th
edition. Springer-Verlag; New York: pp. 170–171. 2001
|
|
34
|
Tjensvoll K, Oltedal S, Farmen RK, et al:
Disseminated tumor cells in bone marrow assessed by TWIST1,
cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in
operable breast cancer patients. Clin Breast Cancer. 10:378–384.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bustin SA, Benes V, Garson JA, et al: The
MIQE guidelines: minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sher YP, Shih JY, Yang PC, et al:
Prognosis of non-small cell lung cancer patients by detecting
circulating cancer cells in the peripheral blood with multiple
marker genes. Clin Cancer Res. 11:173–179. 2005.PubMed/NCBI
|
